{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:35:27Z","timestamp":1780626927988,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute coronary syndrome (ACS) is closely associated with an increased risk of death. Nrg4, a novel adipocytokine, has negative correlations with indicators of metabolic syndrome. Here, we investigated whether circulating Nrg4 associates with the prevalence of ACS. In this case-control study, a total of 257 subjects (144 patients with ACS and 56 patients diagnosed with stable angina pectoris (SAP)) compared to 57 healthy controls. Serum Nrg4 and hs-CRP concentrations were determined by ELISA. The associations of circulating Nrg4 with other clinical parameters were also analyzed. Serum levels of Nrg4 were lower in patients compared to the control subjects (0.7\u2009\u00b1\u20090.53\u2009ng\/mL versus 1.1\u2009\u00b1\u20090.9\u2009ng\/mL, P\u2009=\u20090.018). There was a significant association between higher Nrg4 level and lower risk of ACS (OR\u2009=\u20090.15; 95%CI\u2009=\u20090.02\u20130.9; P\u2009=\u20090.046), but not with SAP. This association was independent of potential confounders including traditional cardiovascular risk factors. The distribution of patients with no, 1, 2 and 3 vessel stenosis was significantly different in Nrg4 quartiles. Patients in the lower quartile of Nrg4 were more likely to experience 3 vessel diseases. Serum levels of Nrg4 correlated negatively with HDL-cholesterol in ACS patients. Decreased serum levels of Nrg4 might be an independent risk factor for ACS.<\/jats:p>","DOI":"10.1038\/s41598-020-62680-x","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T10:04:16Z","timestamp":1585821856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clinical significance of serum concentrations of neuregulin-4, in acute coronary syndrome"],"prefix":"10.1038","volume":"10","author":[{"given":"Mahsa","family":"Rahimzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Farshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadereh","family":"Naderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Farshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Montazerghaem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,2]]},"reference":[{"issue":"1","key":"62680_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ahj.2003.11.027","volume":"148","author":"K Okrainec","year":"2004","unstructured":"Okrainec, K., Banerjee, D. K. & Eisenberg, M. J. Coronary artery disease in the developing world. American heart journal 148(1), 7\u201315 (2004).","journal-title":"American heart journal"},{"issue":"1","key":"62680_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0703-6","volume":"14","author":"C Cai","year":"2016","unstructured":"Cai, C. et al. Association of circulating neuregulin 4 with metabolic syndrome in obese adults: a cross-sectional study. BMC medicine 14(1), 165 (2016).","journal-title":"BMC medicine"},{"key":"62680_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.cyto.2018.10.007","volume":"113","author":"P Yan","year":"2019","unstructured":"Yan, P. et al. Decreased plasma neuregulin 4 levels are associated with peripheral neuropathy in Chinese patients with newly diagnosed type 2 diabetes: A cross-sectional study. Cytokine 113, 356\u2013364 (2019).","journal-title":"Cytokine"},{"issue":"12","key":"62680_CR4","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/nm.3713","volume":"20","author":"G-X Wang","year":"2014","unstructured":"Wang, G.-X. et al. The brown fat\u2013enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. Nature medicine 20(12), 1436 (2014).","journal-title":"Nature medicine"},{"key":"62680_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/srep36710","volume":"6","author":"J Jiang","year":"2016","unstructured":"Jiang, J. et al. Circulating neuregulin 4 levels are inversely associated with subclinical cardiovascular disease in obese adults. Scientific reports 6, 36710 (2016).","journal-title":"Scientific reports"},{"issue":"1","key":"62680_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ando.2016.01.001","volume":"77","author":"B Feve","year":"2016","unstructured":"Feve, B. et al. New adipokines. Ann Endocrinol (Paris) 77(1), 49\u201356 (2016).","journal-title":"Ann Endocrinol (Paris)"},{"key":"62680_CR7","doi-asserted-by":"crossref","unstructured":"Yan, P. et al. Plasma neuregulin 4 levels are associated with metabolic syndrome in patients newly diagnosed with type 2 diabetes mellitus. Disease markers, 2018. 2018.","DOI":"10.1155\/2018\/6974191"},{"key":"62680_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.vph.2015.03.002","volume":"70","author":"M Qin","year":"2015","unstructured":"Qin, M. et al. Myricitrin attenuates endothelial cell apoptosis to prevent atherosclerosis: An insight into PI3K\/Akt activation and STAT3 signaling pathways. Vascular pharmacology 70, 23\u201334 (2015).","journal-title":"Vascular pharmacology"},{"issue":"6","key":"62680_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1159\/000313879","volume":"47","author":"G Tie","year":"2010","unstructured":"Tie, G. et al. Oxidized low-density lipoprotein induces apoptosis in endothelial progenitor cells by inactivating the phosphoinositide 3-kinase\/Akt pathway. J. Vasc Res 47(6), 519\u201330 (2010).","journal-title":"J. Vasc Res"},{"key":"62680_CR10","doi-asserted-by":"crossref","unstructured":"Tian, Q.-P. et al. Association of circulating neuregulin-4 with presence and severity of coronary artery disease. International heart journal, 18\u2013130 (2019).","DOI":"10.1536\/ihj.18-130"},{"issue":"2","key":"62680_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.cell.2009.04.060","volume":"138","author":"K Bersell","year":"2009","unstructured":"Bersell, K. et al. Neuregulin1\/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138(2), 257\u2013270 (2009).","journal-title":"Cell"},{"issue":"6","key":"62680_CR12","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1073\/pnas.0537588100","volume":"100","author":"R Iwamoto","year":"2003","unstructured":"Iwamoto, R. et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proceedings of the National Academy of Sciences 100(6), 3221\u20133226 (2003).","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"11","key":"62680_CR13","doi-asserted-by":"publisher","first-page":"H2139","DOI":"10.1152\/ajpheart.00063.2012","volume":"302","author":"B Wadugu","year":"2012","unstructured":"Wadugu, B. & K\u00fchn, B. The role of neuregulin\/ErbB2\/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. American Journal of Physiology-Heart and Circulatory Physiology 302(11), H2139\u2013H2147 (2012).","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"issue":"2","key":"62680_CR14","doi-asserted-by":"publisher","first-page":"e2622","DOI":"10.1038\/cddis.2017.42","volume":"8","author":"MA Schumacher","year":"2017","unstructured":"Schumacher, M. A. et al. ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammation. Cell death & disease 8(2), e2622 (2017).","journal-title":"Cell death & disease"},{"issue":"1","key":"62680_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11897-013-0176-2","volume":"11","author":"CL Galindo","year":"2014","unstructured":"Galindo, C. L., Ryzhov, S. & Sawyer, D. B. Neuregulin as a heart failure therapy and mediator of reverse remodeling. Current heart failure reports 11(1), 40\u201349 (2014).","journal-title":"Current heart failure reports"},{"issue":"3","key":"62680_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/bdra.20764","volume":"91","author":"KL McBride","year":"2011","unstructured":"McBride, K. L. et al. Association of common variants in ERBB4 with congenital left ventricular outflow tract obstruction defects. Birth Defects Research Part A: Clinical and Molecular Teratology 91(3), 162\u2013168 (2011).","journal-title":"Birth Defects Research Part A: Clinical and Molecular Teratology"},{"issue":"4","key":"62680_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000101776","volume":"44","author":"CM Clement","year":"2007","unstructured":"Clement, C. M. et al. Neuregulin-1 attenuates neointimal formation following vascular injury and inhibits the proliferation of vascular smooth muscle cells. Journal of vascular research 44(4), 303\u2013312 (2007).","journal-title":"Journal of vascular research"},{"key":"62680_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep26242","volume":"6","author":"Y Ma","year":"2016","unstructured":"Ma, Y., Gao, M. & Liu, D. Preventing high fat diet-induced obesity and improving insulin sensitivity through neuregulin 4 gene transfer. Scientific reports 6, 26242 (2016).","journal-title":"Scientific reports"},{"issue":"8","key":"62680_CR19","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.molmet.2017.03.016","volume":"6","author":"Z Chen","year":"2017","unstructured":"Chen, Z. et al. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders. Molecular metabolism 6(8), 863\u2013872 (2017).","journal-title":"Molecular metabolism"},{"issue":"1","key":"62680_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s10238-006-0092-9","volume":"6","author":"A Pasqui","year":"2006","unstructured":"Pasqui, A. et al. Pro-inflammatory\/anti-inflammatory cytokine imbalance in acute coronary syndromes. Clinical and experimental medicine 6(1), 38 (2006).","journal-title":"Clinical and experimental medicine"},{"issue":"6","key":"62680_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/BF01606532","volume":"423","author":"H Kishikawa","year":"1993","unstructured":"Kishikawa, H., Shimokama, T. & Watanabe, T. Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima. Role of cell-mediated immunity in human atherogenesis. Virchows Archiv A 423(6), 433\u2013442 (1993).","journal-title":"Virchows Archiv A"},{"issue":"3","key":"62680_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0167-5273(99)00093-5","volume":"70","author":"K Kato","year":"1999","unstructured":"Kato, K. et al. Elevated levels of pro-inflammatory cytokines in coronary artery thrombi. International journal of cardiology 70(3), 267\u2013273 (1999).","journal-title":"International journal of cardiology"},{"issue":"7","key":"62680_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0753-3322(03)00082-9","volume":"57","author":"X Zhou","year":"2003","unstructured":"Zhou, X. CD4+ T cells in atherosclerosis. Biomed Pharmacother 57(7), 287\u201391 (2003).","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"62680_CR24","first-page":"775","volume":"90","author":"PR Moreno","year":"1994","unstructured":"Moreno, P. R. et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90(2), 775\u2013778 (1994).","journal-title":"Implications for plaque rupture. Circulation"},{"key":"62680_CR25","doi-asserted-by":"crossref","unstructured":"Xu, Y. et al. Neuregulin-1\/ErbB signaling and chronic heart failure, in Advances in Pharmacology, Elsevier. p. 31\u201351 (2010).","DOI":"10.1016\/S1054-3589(10)59002-1"},{"issue":"8","key":"62680_CR26","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0735-1097(02)02164-2","volume":"40","author":"RJ Gibbons","year":"2002","unstructured":"Gibbons, R. J. et al. ACC\/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Journal of the American College of Cardiology 40(8), 1531\u20131540 (2002).","journal-title":"Journal of the American College of Cardiology"},{"key":"62680_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0002-9149(83)80105-2","volume":"51","author":"GG Gensini","year":"1983","unstructured":"Gensini, G. G. A more meaningful scoring system for determining the severity of coronary heart disease. Am J cardiol 51, 606 (1983).","journal-title":"Am J cardiol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62680-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62680-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62680-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:08:22Z","timestamp":1670317702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62680-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,2]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["62680"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-62680-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,2]]},"assertion":[{"value":"21 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5797"}}